Marker Therapeutics, Inc.

Monthly Archives: September 2020

Marker Therapeutics to Present at the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Houston, TX – September 17, 2020– Marker Therapeutics, Inc. (NASDAQ:MRKR),
a clinical-stage immuno-oncology company specializing
in the development of next-generation T cell-based immunotherapies for the
treatment of hematological malignancies and solid tumor indications, today
announced that its President and Chief Executive Officer, Peter L. Hoang, will
present at the upcoming Virtual Oppenheimer Fall Healthcare Life Sciences &…

Read More